We observed that TCGA uterine corpus endometrial carcinoma patients with genetic alterations in BIRC5 had significantly better overall survival rates when compared to TCGA sarcoma and ovarian serous cystadenocarcinoma patients with gene amplification in BIRC5 and EZH2. The median month survival for sarcoma patients with genetic alterations was 32.13 while that of patients without genetic alterations was 76.35. The gene discussed is EZH2; the disease is sarcoma.